Across TCGA pan-cancer cohorts, EIF4A2 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated EIF4A2 data layer compared with 24 for mass-spec protein and 7 for mass-spec protein.
The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher EIF4A2 Mutation is associated with better disease-free survival. In most high-consensus cancer types, elevated EIF4A2 expression acts as an unfavorable survival marker, although some lineages such as UCEC and BLCA show a favorable association.
UCEC, DLBC, and ESCA are the cancer types where EIF4A2 Mutation most reproducibly stratifies survival.